Novartis, Verastem & Cepheid Making Biotech Headlines On Friday
February 13, 2015 at 15:32 PM EST
Novartis AG (ADR) (NYSE: NVS) obtained approval for an accelerated review of an experimental heart-failure treatment Friday, while ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.